H.C. Wainwright analyst Robert Burns raised the firm’s price target on Exelixis (EXEL) to $40 from $29 and keeps a Buy rating on the shares. The firm expects FDA approval for cabozantinib in pancreatic neuroendocrine tumors in April.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- No FDA advisory meeting for Exelixis a positive, says Citi
- Exelixis says cabozantinib sNDA no longer Advisory Committee discussion subject
- Exelixis price target raised to $42 from $33 at Guggenheim
- Exelixis price target raised to $38 from $34 at RBC Capital
- Pony AI, Thermo Fisher initiated: Wall Street’s top analyst calls